Back to Benefits Insider

More High-Cost Therapies Are Coming… But a New Partner is Keeping Us One Step Ahead Featured Image

More High-Cost Therapies Are Coming… But a New Partner is Keeping Us One Step Ahead

With approval rates of high-cost CAR T-cell and gene therapies escalating, the time has come for employers to get proactive about managing their potential risk appropriately.  

CAR T-cell and gene therapies are designed to treat extremely rare diseases such as blood disorders, cancers, and metabolic and neurogenerative diseases by transferring live cells into the body or adding new genes to edit or remove existing genes from the body. 

Depending on the disease, treatment costs can range from $300,000 up to $3 million. However, this does not include the costs associated with administering the treatment or hospitalization – which can range from an additional $300,000 to $800,000, according to Dave McLean, Ph.D., Chief Executive Officer of Emerging Therapy Solutions. 

Emerging Therapy Solutions provides customized forecasts to estimate the risk and utilization of emerging therapies, patient identification tools, clinical and underwriting guidelines. Additionally, their solutions deliver an evaluation process designed to ensure patients can access the right therapy at the right time with negotiated pricing at identified programs of excellence. 

With 20 new therapies expected to come online by the end of 2023 and even more expected in 2024, it has never been more critical for employers to make sure they have a plan in place to manage the associated risks of therapies for rare and complex conditions. 

To learn how Custom Design Benefits and Emerging Therapy Solutions work together to provide employers with a clear path forward, contact your Custom Design Benefits Account Manager.

Back to Benefits Insider